← All trials
NCT05654623
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2022
- Primary completion
- Aug 15, 2024
- Completion date
- May 15, 2028
- First posted
- Dec 16, 2022
- Last posted
- Dec 16, 2022
- Enrollment
- 561
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- PfizerLead sponsor
- PfizerStudy director
- Arvinas IncCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.